Will Morton[email protected]Nuclear MedicineNNSA's Mo-99 program: A bumpy rideLast year was a bumpy ride for a U.S. initiative to secure domestic supplies of molybdenum-99 (Mo-99).October 10, 2024AICanadian physicians wary of AIAbout half of Canadian physicians expressed some enthusiasms over AI, yet 81% said there should be a legal framework for its use in medicine.October 7, 2024Molecular ImagingFES-PET improves management of breast cancer patientsPET/CT imaging with F-18 fluroestradiol (FES) can play a significant role in helping clinicians make treatment decisions in patients with recurrent or metastatic breast cancerOctober 7, 2024Molecular ImagingWhat impact will flurpiridaz F-18 have on heart care?Seventeen years was all it took for flurpiridaz F-18 to reach the market, with the first patient injected with the PET imaging agent in November, 2007.October 4, 2024Digital X-RayCDC considers chest x-ray AI for TB screening programThe U.S. CDC is considering the use of AI to back up its tuberculosis screening program for immigrants and refugees.October 3, 2024AIGPT-4V flops on RSNA ‘Case of the Day’ questionsU.S. National Institutes of Health investigators have found that GPT-4 Vision in its current form is not able to reliably interpret radiologic images.October 1, 2024Molecular ImagingPET identifies risk of metastases in patients with HNSCCPET imaging with F-18 fluoromisonidazole can determine whether cancer may spread in patients undergoing chemoradiotherapy for head and neck squamous cell carcinoma (HNSCC).October 1, 2024Radiation Oncology/TherapyASTRO: Black patients voice distrust in medical researchSpiritual beliefs and a distrust of clinical research may partly explain why Black patients choose not to participate in cancer trials.September 30, 2024Radiation Oncology/TherapyASTRO: IMRT and proton therapy equally effective for prostate cancerIntensity-modulated radiation therapy (IMRT) and proton therapy offer equally high quality of life and tumor control for people with prostate cancer.September 30, 2024Nuclear MedicineFDA approves flurpiridaz F-18 PET tracer for imaging heart diseaseGE HealthCareThe U.S. Food and Drug Administration (FDA) approved the radiotracer flurpiridaz F-18 September 27 for PET imaging of coronary artery disease.September 27, 2024Previous PagePage 26 of 60Next PageTop StoriesMolecular ImagingEANM: Next-generation PET scanner cuts imaging time to one minuteThe scanner's fastest images were rated more highly on average than those from a standard PET/CT scanner.Augmented/Virtual RealityVR boosts accuracy, confidence for evaluating abdominal neuroblastomaMRIMRI shows features of scapular pain in patientsWomens ImagingCEM-guided biopsy effective for sampling suspicious breast findingsDigital X-RayRadiologists, LLMs fail at spotting AI-generated chest x-rays
